Gossamer Bio (GOSS) Share-based Compensation (2018 - 2026)
Gossamer Bio (GOSS) posted quarterly Share-based Compensation of $6.3 million for Q1 2026, up 162.12% year-over-year from $2.4 million in Q1 2025, and up 117.53% quarter-over-quarter from $2.9 million in Q4 2025.
Gossamer Bio (GOSS) Share-based Compensation (2018 - 2026) Analysis & Trends
Gossamer Bio's Share-based Compensation history runs 9 years deep, the most recent figure standing at $6.3 million for Q1 2026.
- In Q1 2026, Share-based Compensation rose 162.12% year-over-year to $6.3 million; the TTM figure through Mar 2026 stood at $14.5 million (down 16.03% YoY), while the FY2025 annual figure was $10.6 million, down 48.81% from the prior year.
- Share-based Compensation for Q1 2026 stood at $6.3 million, up from $2.9 million in the prior quarter.
- The five-year high for Share-based Compensation was $11.0 million in Q1 2022, with the low at -$8.0 million in Q2 2022.
- The 5-year median for Share-based Compensation is $5.0 million (2024), against an average of $4.6 million.
- The sharpest annual moves came in 2023 and 2025: Share-based Compensation soared 203.06% in 2023, then slumped 58.61% in 2025.
- Gossamer Bio's Share-based Compensation stood at -$8.0 million in 2022, then surged by 175.84% to $6.0 million in 2023, then declined by 17.69% to $5.0 million in 2024, then plunged by 41.63% to $2.9 million in 2025, then surged by 117.53% to $6.3 million in 2026.
- Business Quant data shows GOSS's Share-based Compensation at $6.3 million in Q1 2026, $2.9 million in Q4 2025, and $2.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Gossamer Bio | 50.34 Mn | -6.69 Mn | - | 38.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 38.94 Mn |
| Jun 30, 2026 | 38.94 Mn |
| Mar 31, 2026 | 6.30 Mn |
| Mar 31, 2026 | 6.30 Mn |
| Dec 31, 2025 | 2.90 Mn |
| Dec 31, 2025 | 2.90 Mn |
| Sep 30, 2025 | 2.67 Mn |
| Sep 30, 2025 | 2.67 Mn |
| Jun 30, 2025 | 2.59 Mn |
| Jun 30, 2025 | 2.59 Mn |
| Mar 31, 2025 | 2.41 Mn |
| Mar 31, 2025 | 2.41 Mn |
| Dec 31, 2024 | 4.97 Mn |
| Dec 31, 2024 | 4.97 Mn |
| Sep 30, 2024 | 4.84 Mn |
| Sep 30, 2024 | 4.84 Mn |
| Jun 30, 2024 | 5.00 Mn |
| Jun 30, 2024 | 5.00 Mn |
| Mar 31, 2024 | 5.81 Mn |
| Mar 31, 2024 | 5.81 Mn |